20/20 Biolabs Inc. AIDX
—
0.43
0.01
2.38%
as of 25 Sep
- Market cap
- $5.4M
- P/E
- 0.0×
Follow AIDX
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (211.61%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (253.27%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 48.97 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.55) | (0.40) | |
Free Cash Flow |
— | (5.54) | (4.23) | (4.35) | |
Piotroski F-Score |
— | — | — | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | (325.81%) | (58.10%) | (56.43%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 253.90 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 27.45 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 34.15% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 196.05% | |
Share Based Compensation of Revenue |
— | — | — | 34.93% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.67 | |
Depreciation/Fixed assets |
— | 6.61 | 10.83 | 22.54 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | — | 0.00 | 0.20 | |
Operating CF per Share |
0.00 | 0.00 | (0.55) | (0.40) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
— | — | — | (298.16%) |
Columns are period end dates